mw4me logo
Talk to Us | Subscribe | Investment Advisory

Cipla Ltd - Stock Valuation and Financial Performance

BSE: 500087 | NSE: CIPLA | Pharmaceuticals & Drugs | Large Cap

Place order

Cipla Share Price

 ₹1,495.40 -24.05 -1.58%
as on 14-May'25 16:59

DeciZen - make an informed investing decision on Cipla

Overall Rating ⓘ
Bole Toh

1. Quality

Very Good
Check detailed 10 Yrs performace

2. Valuation ⓘ

Overvalued
Check 10 Yrs Valuation charts

3. Price Trend

Semi Strong
Check Price chart

Cipla stock performance -

PE Chart Key Ratios
mw4me loader
P/E Ratio (CD):
22.91
Market Cap:
1,20,774.6 Cr.
52-wk low:
1,310.1
52-wk high:
1,702

Is Cipla Ltd an attractive stock to invest in?

1. Is Cipla Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Cipla Ltd is a good quality company.

2. Is Cipla Ltd undervalued or overvalued?

The key valuation ratios of Cipla Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Cipla Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Cipla Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Cipla:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Standalone Basis P Consolidated Basis P
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Cipla Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
ROCE % ⓘ15.3%13.2%8.3%10.2%11.9%12.5%17.9%17.2%18.2%22.8%-
Value Creation
Index ⓘ		0.40.2-0.3-0.10.10.10.60.50.61.0-

Growth Parameters ⓘ

Growth Parameters Colour Code Guide ⓘ

Sales ⓘ11,34513,59514,39415,15616,36217,13219,16021,76322,75325,77427,145
Sales YoY Gr.-19.8%5.9%5.3%8%4.7%11.8%13.6%4.6%13.3%-
Adj EPS ⓘ13.715.411.416.516.417.129.13032.749.365.3
YoY Gr.-12.3%-26.4%45.1%-0.2%3.9%70.4%3.2%8.9%50.8%-
BVPS (₹) ⓘ133.4142.2155.2175.9185.6194.9226.7257.8289.2329.7386.2
Adj Net
Profit ⓘ		1,1031,2399141,3271,3251,3772,3472,4222,6383,9785,272
Cash Flow from Ops. ⓘ1,1731,7412,3821,4631,6913,0683,7553,3263,2384,134-
Debt/CF from Ops. ⓘ1.531.72.82.60.90.50.30.20.1-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘ9.6%9.5%10.4%13.3%
Adj EPS ⓘ15.3%24.6%19.2%50.8%
BVPSⓘ10.6%12.2%13.3%14%
Share Price 8.1% 21.3% 17% 6.4%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
Return on
Equity % ⓘ		10.611.17.69.99.1913.812.411.915.918.2
Op. Profit
Mgn % ⓘ		19.118.217.618.718.918.722.220.721.924.426.3
Net Profit
Mgn % ⓘ		10.49.46.68.88812.211.311.715.619.4
Debt to
Equity ⓘ		0.20.50.30.30.30.20.10000
Working Cap
Days ⓘ		248220200210151140134135146145147
Cash Conv.
Cycle ⓘ		112107106103595352565249111

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 18.60%

Sales growth is growing at healthy rate in last 3 years 10.39%

Net Profit is growing at healthy rate in last 3 years 19.20%

Sales growth is not so good in last 4 quarters at 6.70%

Latest Financials - Cipla Ltd.

Standalone Consolidated
TTM EPS (₹) 63.9 65.3
TTM Sales (₹ Cr.) 16,111 27,145
BVPS (₹.) ⓘ 397.4 386.2
Reserves (₹ Cr.) ⓘ 31,938 31,032
P/BV ⓘ 3.76 3.87
PE ⓘ 23.42 22.91
From the Market
52 Week Low / High (₹) 1310.05 / 1702.00
All Time Low / High (₹) 2.22 / 1702.00
Market Cap (₹ Cr.) 1,20,775
Equity (₹ Cr.) 161.5
Face Value (₹) 2
Industry PE ⓘ 39.4

Management X-Ray of Cipla:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Cipla

Event Update

Login/Register to view analysis.

Analyst's Notes

Cipla: Q2FY25 Results Update - 04 Nov 2024

Numbers are calculated without adjusting for the divestment of QCIL in Q3FY24. As a result, growth numbers and changes in margin may differ than those reported in the Q2FY25 presentation.

Business Segment Highlights

  • One India Business: Growth in this segment was slower due to seasonal factors, particularly in the acute category. The overall growth was recorded at 5% year-on-year. However, chronic therapies showed better performance with respiratory growing by 9%, cardiac by 11%, and urology by 15%.

  • North America Market: Revenue reached $237 million in Q2FY25 from $229 million in in Q2FY24, supported by a strong differentiated portfolio despite temporary supply challenges with Lanreotide.

  • Africa Operations: The newly merged One Africa business recorded a robust growth of 22%, with South Africa's private market ranking second overall.

Regulatory and Operational Updates

  • Cipla is addressing regulatory inspections with ongoing remediation efforts at its facilities. The Goa facility recently received six observations from the US FDA during re-inspection and was classified as Voluntary Action Indicated (VAI).This will lead to the launch of Abraxane, a cancer drug with a market size of over $700 million.

  • The company is focused on resolving supply issues related to Lanreotide and is optimistic about recovery in sales starting from Q4 FY25.

Strategic Focus Areas

  • Cipla aims to maintain its trajectory of outpacing market growth in branded prescriptions while enhancing its trade generics business.

  • Continued investments in R&D were highlighted, with expenditures amounting to Rs. 385 crore or 5.5% of revenue for the quarter.

Cipla's management expressed confidence in achieving their margin guidance for the year, which is projected between 24.5% and 25.5%. They are optimistic about future growth driven by strategic investments and operational improvements across their key markets.

Cipla: Q1FY25 Update - 20 Aug 2024

Q1FY25 Concall Highlights:

  1. Capex: The company expects the capex to increase to Rs. 1500-1800 crores annually, with 70% earmarked for growth and 30% earmarked for compliance. This is above the historical run rate of Rs. 1000-1200 crores. 

  2. Product Launches: Cipla launched the generic version of Lanreotide (Market Size ~1.4bn USD) injection in Q1FY25. Two more peptides are expected to be launched by the end of the year. The company currently has a non-generic version of Lanreotide in the US market with a 20%+ market share.

  3. Price erosion: The company has witnessed a price erosion of 10% YoY and 5-6% QoQ and expects price erosion to remain in single digits going forward. The company does not expect price erosion in Albuterol due to segmentation of the market.

Cipla Ltd.: Q4 FY24 Result Update - 22 May 2024

Particulars

Q4FY24 (Rs.Cr)

YoY(%) Trend

Comments

Revenue

6163

+7.4%

 

EBITDA

1316

+12%

 

EBITDA Margin (%)

21%

+89 bps

 

PAT

932

+78.5%

Low Base due to Exceptional Items

Cipla Quarterly Call: Key Takeaways

  1. One India: The Consumer Health division was affected by seasonality but maintained profitability. Cipla expects that a recovery in demand and inorganic growth initiatives will help scale up this segment. The company has also changed its trade generics sales model to increase direct market interactions. The branded prescription business continued to outpace market growth, driven by cardiac and respiratory therapies, with chronic therapies now accounting for 61% of the product portfolio, up 100 bps year-over-year. 
  2. North America: Cipla reported record annual revenue of USD 906 million in FY24, a 24% year-over-year increase. Lanreotide achieved a market share of 20.8% as of February 2024, and Albuterol’s market share increased from 12%-13% at the end of FY24 to 15.5% in April 2024. Cipla remains one of the fastest-growing companies among the top 5 in the US. 
  3. South Africa: Cipla achieved a leadership position in the prescription business in South Africa, recording an 11.2% year-over-year growth in the secondary market, compared to the overall market growth of 2.1% year-over-year.
  4. Product Pipeline: Research and development spending will be 6-7% of revenue in FY25. Cipla has filed five respiratory assets, including Symbicort, with launches expected within 1-3 years. The company has also filed 12 assets in the peptide and complex generics space, with most launches anticipated over the next 2-4 years. The launch of gAbraxane depends on USFDA clearance of the Goa facility, expected by the end of Mar-Jun ‘26 following re-inspection in Jul-Sept’25
  5. Capital Expenditure: Cipla’s capital investments stood at Rs. 13,150 million in FY24. The company plans to increase its capital expenditure to Rs. 15,000 million in FY25.
  6. Guidance: The company has guided EBITDA margins between 24.5% and 25.5%.

We maintain our MRP of 1196 after factoring the business updates.

Cipla reports 32% rise in Q3 consolidated net profit - 23 Jan 2024

Cipla has reported results for third quarter ended December 31, 2023 (Q3FY24).

The company has reported 64.20% rise in net profit at Rs 1114.14 crore for the quarter ended December 31, 2023 as compared to Rs 678.52 crore for the same quarter in the previous year. Total income of the company increased by 24.23% at Rs 4550.31 crore for Q3FY24 as compared Rs 3662.85 crore for corresponding quarter of the previous year.

On consolidated basis, the company reported 32.26% rise in its net profit at Rs 1068.41 crore for Q3FY24 as compared to Rs 807.83 crore for the same quarter in the previous year. Total income of the company increased by 14.58% at Rs 6788.44 crore for Q3FY24 as compared Rs 5924.53 crore for corresponding quarter of the previous year.

Cipla: Q2FY24 result update - 04 Nov 2023

                                    

Particulars

Q2FY24 (Rs. Crs)

YoY Trend

Comments

Revenue

6,678

+15%

Strong growth across domestic and international markets 
EBITDA

1,734

+33%

 
EBITDA Margin

26%

+362 bps

Low raw material costs, operating leverage benefits supported margins
PAT

1,155

+45%

Aided by other income and lower depreciation on strategic divestments 

Robust results. 

Cipla Ltd: Q1FY24 Result Update - 28 Jul 2023

Particulars

Q1FY24

YoY trend

Comment

Revenue

6,329

+18%

Domestic branded growth 12% and healthy 43% growth across US markets  

EBITDA

1,494

+30%

 

EBITDA Margin

24%

+230 bps

Gross margins improved on back of better product mix 

PAT

998

+41%

 

Stellar performance on all fronts. Traction driven by chronic therapy solutions in domestic market as well as better execution in base business. Higher-than-expected revenue contribution from gRevlimid (myeloma cancer medication) also aided growth.

 

View All Notes

Key Ratios of Cipla

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
Standalone Basis Consolidated Basis
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Sales11,34513,59514,39415,15616,36217,13219,16021,76322,75325,774
Operating Expenses ⓘ 9,18411,11511,91912,32913,26513,95114,91117,25117,76319,483
Manufacturing Costs9651,2691,4451,5191,6201,6991,5151,7841,9442,144
Material Costs4,2715,0905,3175,4385,7845,9917,3528,4968,2528,820
Employee Cost 1,9682,4342,6342,6902,8573,0273,2523,5303,8304,310
Other Costs ⓘ 1,9802,3222,5232,6813,0043,2332,7933,4423,7374,209
Operating Profit ⓘ 2,1622,4802,4762,8263,0973,1814,2494,5124,9906,291
Operating Profit Margin (%) 19.1%18.2%17.2%18.6%18.9%18.6%22.2%20.7%21.9%24.4%
Other Income ⓘ 166208229358477369270322512747
Interest ⓘ 16820715911416819716110611090
Depreciation ⓘ 5057541,3231,3231,3261,1751,0681,0521,1721,051
Exceptional Items ⓘ 000-78000-182-182-195
Profit Before Tax ⓘ 1,6541,7271,2221,6692,0792,1783,2903,4934,0385,702
Tax ⓘ 4003321802505706318899341,2031,547
Profit After Tax 1,2541,3951,0421,4191,5101,5472,4012,5592,8354,155
PAT Margin (%) 11.1%10.3%7.2%9.4%9.2%9.0%12.5%11.8%12.5%16.1%
Adjusted EPS (₹)14.716.912.517.519.019.229.831.234.751.1
Dividend Payout Ratio (%)14%12%16%17%16%21%17%16%24%25%

Balance Sheet

(All Figures are in Crores.)
Standalone Basis Consolidated Basis
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24

Equity and Liabilities

Shareholders Fund 10,71811,42712,48214,16314,95515,71018,28420,79823,34626,620
Share Capital ⓘ 161161161161161161161161161161
Reserves ⓘ 10,55811,26612,32114,00214,79415,54918,12320,63623,18526,458
Minority Interest18035043835233229425927630696
Debt1,7025,1924,1134,0984,3162,8161,537810188247
Long Term Debt3092223,6453,6623,8302,3691,20341600
Short Term Debt1,3924,970467436486447335393188247
Trade Payables1,4521,4761,5712,1191,9482,2822,0672,5082,5352,474
Others Liabilities ⓘ 3,2282,6052,2651,9402,2102,3202,6892,2612,6332,693
Total Liabilities ⓘ 17,28121,04920,86922,67323,76223,42324,83726,65229,00732,130

Fixed Assets

Gross Block9,56210,16811,35312,96013,79014,91415,64716,96817,20518,161
Accumulated Depreciation2,7327991,6103,0114,2345,3096,2177,3117,9958,574
Net Fixed Assetsⓘ 6,8309,3689,7439,9499,5579,6049,4309,6589,2109,587
CWIP ⓘ 5812,0611,6839816768259697661,0931,153
Investmentsⓘ 6397589731,2592,5541,4712,7102,5513,6625,449
Inventories3,7813,8083,4854,0453,9654,3784,6695,3505,1565,238
Trade Receivables1,9982,3562,5633,1024,1513,8913,4463,4244,0574,771
Cash Equivalents 5648716249666191,0041,4011,9281,565875
Others Assetsⓘ 2,8891,8271,7972,3712,2412,2502,2122,9754,2635,057
Total Assets ⓘ 17,28121,04920,86922,67323,76223,42324,83726,65229,00732,130

Cash Flow

(All Figures are in Crores.)
Standalone Basis Consolidated Basis
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Cash Flow From Operating Activity ⓘ 1,1731,7412,3821,4631,6913,0683,7553,3263,2384,134
PBT ⓘ 1,6541,7271,2221,6692,0792,1783,2903,6754,2215,897
Adjustment ⓘ 6309511,3741,2941,2691,3661,131967878641
Changes in Working Capital ⓘ -719-429235-778-1064373372-177-559-806
Tax Paid ⓘ -392-508-450-722-593-848-1,037-1,140-1,302-1,597
Cash Flow From Investing Activity ⓘ -941-4,523-1,310-854-1,669104-2,387-1,872-2,389-2,988
Capex -626-1,053-1,098-739-504-986-791-681-1,134-1,315
Net Investments -380-64-282-1,0641,029-1,675153-913-1,473
Others ⓘ -278-3,470-148167-1016180-1,343-341-200
Cash Flow From Financing Activityⓘ 1653,104-1,326-385-349-2,949-1,240-1,600-958-1,200
Net Proceeds from Shares ⓘ 123120000000
Net Proceeds from Borrowing ⓘ 7-663,420-3-58-1,736-951-1,041-440
Interest Paid ⓘ -167-161-159-118-159-164-121-76-65-65
Dividend Paid ⓘ -161-159-161-161-242-5640-403-404-686
Others ⓘ 4743,488-4,438-104109-485-168-80-446-449
Net Cash Flow ⓘ 397322-254223-326224129-146-109-55

Finance Ratio

Standalone Basis Consolidated Basis
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Ratios
ROE (%)12.112.618.7210.6510.3710.0914.1313.112.8516.63
ROCE (%)15.3313.248.2810.211.9412.5317.8517.2418.1922.77
Asset Turnover Ratio0.720.720.70.71.031.151.171.151.111.16
PAT to CFO Conversion(x)0.941.252.291.031.121.981.561.31.140.99
Working Capital Days
Receivable Days58586168555447424445
Inventory Days1061009190615658626254
Payable Days10410510512412812910898112104

Cipla Ltd Stock News

Cipla Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Cipla on 14-May-2025 16:59 is ₹1,495.4.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 14-May-2025 16:59 the market cap of Cipla stood at ₹1,20,774.6.
The latest P/E ratio of Cipla as of 14-May-2025 16:59 is 23.42.
The latest P/B ratio of Cipla as of 14-May-2025 16:59 is 3.76.
The 52-week high of Cipla is ₹1,702 and the 52-week low is ₹1,310.1.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Cipla is ₹16,111 ( Cr.) .

About Cipla Ltd

Cipla Limited is a global pharmaceutical company focused on responsible and sustainable growth of complex generics and deepening portfolio in home markets of India, South Africa and North America, as well as key regulated and emerging markets. Equity Shares of the Company are listed on Bombay Stock Exchange Limited and National Stock Exchange of India Limited.

Business area of the company

The company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company has its wide network of manufacturing, trading and other incidental operations in India and International markets.

Products

  • Generics and branded generics
  • Specialty
  • Consumer health

Awards:

2013:

  • Ernst & Young awarded Dr. Y K Hamied with the Lifetime Achievement Award of the year 2013
  • Dr. Hamied honoured with the Greatest Global Indian Living Legend Award by NDTV
  • Viragaonagar unit won the Excellence Award in Environment Health & Safety (EHS)
  • Bagged the prestigious LegalEra Award for the Best Pharmaceutical in-house Legal team.

2014

  • Cipla won the Global L&D Team of the Year Award
  • Brand, Azee bagged the Marketing Excellence Award in 2014
  • Won the 'Silver' award from Pharmexcil for Outstanding Performance in the export of Pharmaceuticals
  • Network 18 and Infosys awarded Cipla for innovation on HIV/AIDS drugs

2015:

  • Won the Award for Excellence in Rural Reach at India Pharma Awards
  • Accredited to be in Top 10 of Hot 50 Brands in Mumbai, under ‘Large Organization Category’ at the Mumbai Brand Summit
  • Won the Social Contributors Award at the Annual Pitch Top 50 Brands Awards organized by Dainik Bhaskar
  • Best Company Award to focus in Overall Nursing Home Development at the first ever CIMS Healthcare Excellence Awards
  • ABP News honored Dr. Y.K. Hamied with the ‘Lifetime Achievement Award’ at the Brand Excellence Awards 2015

2016:

  • The Indian Manufacturers’ Association (IDMA) honoured Dr. Hamied with IDMA Lifetime Achievement Award for his outstanding contribution to the Indian pharmaceutical industry.
  • Moroccan Society of ENT honoured Cipla Morocco team for contribution to the education of the physics.
  • Dr. Y.K. Hamied was honoured with the Lifetime Achievement Award at the Forbes India Leadership Awards 2016.
  • Won two awards for Supplier Relationship Management and People Management at the CPO Awards 2016
  • Received an award for Acnedep Gel packaging at the 'India Packaging Awards' 2016
  • Won the ABP News Healthcare Leadership Award for excellence in managing Primary Care Practitioners

2017:

  • Digital team bagged two of the most prestigious awards of the digital world - Digital Pioneer of the year 2017 and Best company for leveraging technology in mobile application.
  • ActivKids Immuno Boosters won the Emerging Nutrition Brand of the Year awarded by CIMS.
  • Cipla Health won a place in the Economic Times Best Asian Healthcare Brands 2017

2018:

  • India Packaging Awards for Excellence in Enhanced User Experience for Mesalo Foam packaging
  • Silver Plasticon Award 2018 for Excellence and Innovation in flexible packaging for Acnedap Plus
  • SCMPro Logistics and Supply Chain Awards for 'Excellence in Pharma Supply Chain Management, Procurement Transformation of the Year' and 'Best Sourcing Analytics'.
  • Global Logistics Excellence Award for 'Best Digital Transformation in Pharma' in the Supply Chain Practitioners category
  • Breathefree website bags DMA Asia Echo Award (Silver) for Best Digital Destination and Leader Certificate in Pharma & Healthcare category
  • India Pharma Awards for Breathefree - 'Best Patient Outreach Programme of the Year', Digital Innovation
  • Indian Digital Awards (IDA) for Excellence in Digital Publishing
  • ABP News Healthcare Leadership Award for Excellence in Improving Awareness, Detection of Health Issues and Adherence to Treatment Regimen in the Emerging Markets

2019:

  • Cipla receives the 18th ICSI (Institute of Company Secretaries of India) National Award for Excellence in Corporate Governance in January 2019.
  • Highly Commended - 'Best Working Capital Management Solution Award' at the Adam Smith Awards Asia 2019
  • 'Innovation in Generics' Award for Sereflo at the UK Pharmacy Business Awards 2019
  • ‘Indo-American Corporate Excellence Award' for Excellence in Manufacturing (Category II) by the Indo-American Chamber of Commerce
  • Most Outstanding Company in India - Healthcare category at the Asiamoney Asia’s Outstanding Companies Poll 2019

2020:

  • Cipla Sri Lanka is Great Place to Work Certified
  • Cipla is Great Place to Work Certified
  • ‘Digital Supply Chain Enterprise Award’ at the 9th edition of the Manufacturing Supply Chain Awards 2020
  • Golden Peacock Award for CSR 2019 in recognition of Cipla Foundation's significant contribution towards social change
  • What’s Up Cipla bags the 'Best Small Idea, Big Impact Communication of the Year' at the Corp Comm & PR Excellence Awards 2020
  • The Institute of Chartered Accountants of India Award for Excellence in Financial Reporting 2018-19 under the category of companies publishing integrated annual report

Milestones

  • 1935: Operations commence from a rented bungalow at 289, Bellasis Road, Bombay Central.
  • 1939: Mahatma Gandhi visits Cipla, inspiring the Founder Dr K A Hamied to produce vital and life-saving medicines for India.
  • 1947: Cipla celebrates India attaining Independence with a flag hoisting ceremony at Bombay Central Headquarters.
  • 1970: Cipla becomes one of the pioneers to manufacture APIs (active pharmaceutical ingredients).
  • 1977: Inauguration of the Cipla Research and Production Complex in Bangalore by Mrs. Luba K Hamied.
  • 1997: Cipla Palliative Care and Training Centre is set up in Pune to provide free holistic care to terminally-ill cancer patients and their families.
  • 2001: Cipla ushers in a new paradigm in antiretroviral therapy (ART) by offering the triple ARV FDC at USD 1-a-day, thus opening the floodgates for affordability and accessibility in HIV/AIDS treatment.
  • 2013: Cipla acquires 100% of share capital of Cipla Medpro (South Africa).
  • 2016: Cipla strengthens its presence in the US market with the acquisition of InvaGen Pharmaceuticals Inc. and Exelan Pharmaceuticals Inc. thus expanding its reach in the US market, with a balanced portfolio.
  • 2017: Cipla launches Synchrobreathe, a state of-the-art innovative breath-actuated inhaler, helping millions with Obstructive Airway Diseases such as asthma.
  • 2019: Cipla enters digital therapeutics by partnering with Wellthy Therapeutics in India and Brandmed in South Africa to bring together behavioural science, real world clinical evidence and artificial intelligence to provide real time monitoring, coaching and advice to patients.
  • 2020: Cipla leads the fight against COVID-19 through a spectrum of vital drugs that show potency against the virus. With unmatched portfolio of drugs and devices and leadership across India and key emerging markets, Cipla launches global lung leadership aspiration - Breathe. Think Cipla. In the US, the approval for generic AIbuterol MDI and successful Phase-3 completion of clinical study for generic Advair Diskus furthers this ambition.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
Compliance Officer:
Name: Shrikant Jagtap
Email : shrikant.jagtap@moneyworks4me.com
Mobile No: +91 97638 00745
Grievance officer:
Name: Mukta Vaze
Email : mukta.vaze@moneyworks4me.com
Mobile No:+91 98609 19463
Principal Officer:
Name: Atharva Bhide
Email : atharva.bhide@moneyworks4me.com
Mobile No:+91 91758 99463
Sitemap play-store Download APP play-store Download APP
linkedin facebook twitter youtube insta whatsapp
Address: The Alchemists Ark Pvt. Ltd., B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Complaints: Complaint status | Cancellation and Refund Policy | PML Act | Grievance Redressal Process | ODR | Investor charter | Terms & Conditions | Disclaimer | Disclosure
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...